{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:19:00Z","timestamp":1783099140539,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2016-Kolleg-19"],"award-info":[{"award-number":["2016-Kolleg-19"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008001","name":"Universit\u00e4t zu K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008001","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with locally advanced esophageal or gastroesophageal adenocarcinoma benefit from multimodal therapy concepts including neoadjuvant chemoradiation (nCRT), respectively, perioperative chemotherapy (pCT). However, it remains unclear which treatment is superior concerning postoperative morbidity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study, we compared the postsurgical survival (30-day\/90-day\/1-year mortality) (primary endpoint), treatment response, and surgical complications (secondary endpoints) of patients who either received nCRT (CROSS protocol) or pCT (FLOT protocol) due to esophageal\/gastroesophageal adenocarcinoma. Between January 2013 and December 2017, 873 patients underwent Ivor Lewis esophagectomy in our high-volume center. 339 patients received nCRT and 97 underwent pCT. After 1:1 propensity score matching (matching criteria: sex, age, BMI, ASA score, and Charlson score), 97 patients per subgroup were included for analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After matching, tumor response (ypT\/ypN) did not differ significantly between nCRT and pCT (<jats:italic>p<\/jats:italic>\u2009=\u20090.118, respectively, <jats:italic>p<\/jats:italic>\u2009=\u20090.174). Residual nodal metastasis occurred more often after pCT (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). Postsurgical mortality was comparable within both groups. No patient died within 30 or 90\u00a0days after surgery while the 1-year survival rate was 72.2% for nCRT and 68.0% for pCT (<jats:italic>p<\/jats:italic>\u2009=\u20090.47). Only grade 3a complications according to Clavien\u2013Dindo were increased after pCT (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). There was a trend towards a higher rate of pylorospasm within the pCT group (nCRT: 23.7% versus pCT: 37.1%) (<jats:italic>p<\/jats:italic>\u2009=\u20090.061). Multivariate analysis identified pCT, younger age, and Charlson score as independent variables for pylorospasm.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Both nCRT and pCT are safe and efficient within the multimodal treatment of esophageal\/gastroesophageal adenocarcinoma. We did not observe differences in postoperative morbidity. However, functional aspects such as gastric emptying might be more frequent after pCT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03720-5","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T11:03:02Z","timestamp":1625482982000},"page":"1223-1234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis"],"prefix":"10.1007","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8165-4553","authenticated-orcid":false,"given":"Patrick Sven","family":"Plum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Damanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Buschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi Raj","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Mortimer","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hun","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Alakus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf Heinrich","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane Josephine","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bludau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"3720_CR1","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","volume":"19","author":"S-E Al-Batran","year":"2008","unstructured":"Al-Batran S-E, Hartmann JT, Hofheinz R et al (2008) Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19:1882\u20131887. https:\/\/doi.org\/10.1093\/annonc\/mdn403","journal-title":"Ann Oncol"},{"key":"3720_CR2","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"S-E Al-Batran","year":"2016","unstructured":"Al-Batran S-E, Hofheinz RD, Pauligk C et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO. Lancet Oncol 17:1697\u20131708. https:\/\/doi.org\/10.1016\/S1470-2045(16)30531-9","journal-title":"Lancet Oncol"},{"key":"3720_CR3","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra. Lancet 393:1948\u20131957. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1","journal-title":"Lancet"},{"key":"3720_CR4","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1245\/s10434-017-5827-1","volume":"24","author":"MCJ Anderegg","year":"2017","unstructured":"Anderegg MCJ, van der Sluis PC, Ruurda JP et al (2017) Preoperative chemoradiotherapy versus perioperative chemotherapy for patients with resectable esophageal or gastroesophageal junction adenocarcinoma. Ann Surg Oncol 24:2282\u20132290. https:\/\/doi.org\/10.1245\/s10434-017-5827-1","journal-title":"Ann Surg Oncol"},{"key":"3720_CR5","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/ajg.2017.155","volume":"112","author":"M Arnold","year":"2017","unstructured":"Arnold M, Laversanne M, Brown LM et al (2017) Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030. Am J Gastroenterol 112:1247\u20131255. https:\/\/doi.org\/10.1038\/ajg.2017.155","journal-title":"Am J Gastroenterol"},{"key":"3720_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ejca.2010.09.009","volume":"47","author":"BH Burmeister","year":"2011","unstructured":"Burmeister BH, Thomas JM, Burmeister EA et al (2011) Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 47:354\u2013360. https:\/\/doi.org\/10.1016\/j.ejca.2010.09.009","journal-title":"Eur J Cancer"},{"key":"3720_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2017.07.046","volume":"154","author":"HG Coleman","year":"2018","unstructured":"Coleman HG, Xie SH, Lagergren J (2018) The epidemiology of esophageal adenocarcinoma. Gastroenterology 154:390\u2013405. https:\/\/doi.org\/10.1053\/j.gastro.2017.07.046","journal-title":"Gastroenterology"},{"key":"3720_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205\u2013213. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae","journal-title":"Ann Surg"},{"key":"3720_CR9","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.ejso.2017.06.003","volume":"43","author":"F Favi","year":"2017","unstructured":"Favi F, Bollschweiler E, Berlth F et al (2017) Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study. Eur J Surg Oncol 43:1572\u20131580. https:\/\/doi.org\/10.1016\/j.ejso.2017.06.003","journal-title":"Eur J Surg Oncol"},{"key":"3720_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","volume":"16","author":"J Hoeppner","year":"2016","unstructured":"Hoeppner J, Lordick F, Brunner T et al (2016) ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 16:503. https:\/\/doi.org\/10.1186\/s12885-016-2564-y","journal-title":"BMC Cancer"},{"key":"3720_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/SLA.0b013e3182369128","volume":"254","author":"AH H\u00f6lscher","year":"2011","unstructured":"H\u00f6lscher AH, Bollschweiler E, Schr\u00f6der W et al (2011) Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg 254:802\u2013807. https:\/\/doi.org\/10.1097\/SLA.0b013e3182369128 (discussion 807-8)","journal-title":"Ann Surg"},{"key":"3720_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/annonc\/mdw010","volume":"27","author":"F Klevebro","year":"2016","unstructured":"Klevebro F, von D\u00f6beln GA, Wang N et al (2016) A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 27:660\u2013667. https:\/\/doi.org\/10.1093\/annonc\/mdw010","journal-title":"Ann Oncol"},{"key":"3720_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-019-1693-6","volume":"17","author":"OO Koch","year":"2019","unstructured":"Koch OO, Weitzendorfer M, Varga M et al (2019) Perioperative chemotherapy versus neoadjuvant chemoradiation for patients with adenocarcinoma of the distal esophagus in Austria: A retrospective analysis. World J Surg Oncol 17:1\u20139. https:\/\/doi.org\/10.1186\/s12957-019-1693-6","journal-title":"World J Surg Oncol"},{"key":"3720_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1529-x","volume":"15","author":"T Leong","year":"2015","unstructured":"Leong T, Smithers BM, Michael M et al (2015) TOPGEAR: A randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG\/TROG\/EORTC\/NCIC CTG). BMC Cancer 15:1\u20136. https:\/\/doi.org\/10.1186\/s12885-015-1529-x","journal-title":"BMC Cancer"},{"key":"3720_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008929","volume":"96","author":"J Liu","year":"2017","unstructured":"Liu J, Xue L, Zhen F, Luo J (2017) Efficacy and safety of chemoradiation therapy compared with chemotherapy for esophageal carcinoma. Medicine (baltimore) 96:e8929. https:\/\/doi.org\/10.1097\/MD.0000000000008929","journal-title":"Medicine (baltimore)"},{"key":"3720_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/SLA.0000000000001098","volume":"262","author":"DE Low","year":"2015","unstructured":"Low DE, Alderson D, Cecconello I et al (2015) International consensus on standardization of data collection for complications associated with esophagectomy: esophagectomy complications consensus group (ECCG). Ann Surg 262:286\u2013294. https:\/\/doi.org\/10.1097\/SLA.0000000000001098","journal-title":"Ann Surg"},{"key":"3720_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/SLA.0000000000002611","volume":"269","author":"DE Low","year":"2019","unstructured":"Low DE, Kuppusamy MK, Alderson D et al (2019) Benchmarking complications associated with esophagectomy. Ann Surg 269:291\u2013298. https:\/\/doi.org\/10.1097\/SLA.0000000000002611","journal-title":"Ann Surg"},{"key":"3720_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/annonc\/mdw560","volume":"28","author":"SR Markar","year":"2017","unstructured":"Markar SR, Noordman BJ, Mackenzie H et al (2017) Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study. Ann Oncol 28:519\u2013527. https:\/\/doi.org\/10.1093\/annonc\/mdw560","journal-title":"Ann Oncol"},{"key":"3720_CR19","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1007\/s00268-016-3575-1","volume":"40","author":"MKH Maus","year":"2016","unstructured":"Maus MKH, Leers J, Herbold T et al (2016) Gastric outlet obstruction after esophagectomy: retrospective analysis of the effectiveness and safety of postoperative endoscopic pyloric dilatation. World J Surg 40:2405\u20132411. https:\/\/doi.org\/10.1007\/s00268-016-3575-1","journal-title":"World J Surg"},{"key":"3720_CR20","doi-asserted-by":"publisher","first-page":"e0002","DOI":"10.5041\/RMMJ.10339","volume":"10","author":"S Nusrath","year":"2019","unstructured":"Nusrath S, Thammineedi SR, Vijaya Narsimha Raju KV et al (2019) Short-term outcomes in patients with carcinoma of the esophagus and gastroesophageal junction receiving neoadjuvant chemotherapy or chemoradiation before surgery. A prospective study. Rambam Maimonides Med J 10:e0002. https:\/\/doi.org\/10.5041\/RMMJ.10339","journal-title":"Rambam Maimonides Med J"},{"key":"3720_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10120-018-0901-3","volume":"22","author":"F Petrelli","year":"2019","unstructured":"Petrelli F, Ghidini M, Barni S et al (2019) Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis. Gastric Cancer 22:245\u2013254. https:\/\/doi.org\/10.1007\/s10120-018-0901-3","journal-title":"Gastric Cancer"},{"key":"3720_CR22","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1007\/s00464-018-6139-7","volume":"32","author":"PS Plum","year":"2018","unstructured":"Plum PS, H\u00f6lscher AH, Pacheco Godoy K et al (2018) Prognosis of patients with superficial T1 esophageal cancer who underwent endoscopic resection before esophagectomy\u2013a propensity score-matched comparison. Surg Endosc 32:3972\u20133980. https:\/\/doi.org\/10.1007\/s00464-018-6139-7","journal-title":"Surg Endosc"},{"key":"3720_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12885-017-3386-2","volume":"17","author":"JV Reynolds","year":"2017","unstructured":"Reynolds JV, Preston SR, O\u2019Neill B et al (2017) ICORG 10\u201314: NEOadjuvant trial in adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer 17:401. https:\/\/doi.org\/10.1186\/s12885-017-3386-2","journal-title":"BMC Cancer"},{"key":"3720_CR24","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/01.sla.0000186170.38348.7b","volume":"242","author":"PM Schneider","year":"2005","unstructured":"Schneider PM, Baldus SE, Metzger R et al (2005) Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification. Ann Surg 242:684\u2013692. https:\/\/doi.org\/10.1097\/01.sla.0000186170.38348.7b","journal-title":"Ann Surg"},{"key":"3720_CR25","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof MCCM et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16:1090\u20131098. https:\/\/doi.org\/10.1016\/S1470-2045(15)00040-6","journal-title":"Lancet Oncol"},{"key":"3720_CR26","volume-title":"tnm classification of malignant tumours","author":"LH Sobin","year":"2009","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C (2009) tnm classification of malignant tumours, 7th edn. Wiley, Hoboken","edition":"7"},{"key":"3720_CR27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","volume":"27","author":"M Stahl","year":"2009","unstructured":"Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851\u2013856. https:\/\/doi.org\/10.1200\/JCO.2008.17.0506","journal-title":"J Clin Oncol"},{"key":"3720_CR28","doi-asserted-by":"publisher","first-page":"9989","DOI":"10.1007\/s11033-012-1866-7","volume":"39","author":"EZ Sung","year":"2012","unstructured":"Sung EZ, Arasaradnam RP, Jarvie EM et al (2012) Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function. Mol Biol Rep 39:9989\u20139994. https:\/\/doi.org\/10.1007\/s11033-012-1866-7","journal-title":"Mol Biol Rep"},{"key":"3720_CR29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.athoracsur.2010.04.061","volume":"90","author":"SG Swisher","year":"2010","unstructured":"Swisher SG, Hofstetter W, Komaki R et al (2010) Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg 90:892\u2013899. https:\/\/doi.org\/10.1016\/j.athoracsur.2010.04.061","journal-title":"Ann Thorac Surg"},{"key":"3720_CR30","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/SLA.0000000000000965","volume":"260","author":"AK Talsma","year":"2014","unstructured":"Talsma AK, Shapiro J, Looman CWN et al (2014) Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg 260:786\u2013793. https:\/\/doi.org\/10.1097\/SLA.0000000000000965","journal-title":"Ann Surg"},{"key":"3720_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/0284186X.2019.1698765","volume":"59","author":"T van den Ende","year":"2020","unstructured":"van den Ende T, Hulshof MCCM, van Berge Henegouwen MI et al (2020) Gastro-oesophageal junction: to FLOT or to CROSS? Acta Oncol 59:233\u2013236. https:\/\/doi.org\/10.1080\/0284186X.2019.1698765","journal-title":"Acta Oncol"},{"key":"3720_CR32","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P Van Hagen","year":"2012","unstructured":"Van Hagen P, Hulshof MCCM, Van Lanschot JJB et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074\u20132084. https:\/\/doi.org\/10.1056\/NEJMoa1112088","journal-title":"N Engl J Med"},{"key":"3720_CR33","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/jso.25089","volume":"117","author":"E Visser","year":"2018","unstructured":"Visser E, Edholm D, Smithers BM et al (2018) Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. J Surg Oncol 117:1687\u20131696. https:\/\/doi.org\/10.1002\/jso.25089","journal-title":"J Surg Oncol"},{"key":"3720_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5090\/kjtcs.2020.53.4.226","volume":"53","author":"HC Yang","year":"2020","unstructured":"Yang HC, Choi JH, Kim MS, Lee JM (2020) Delayed gastric emptying after esophagectomy: management and prevention. Korean J Thorac Cardiovasc Surg 53:226\u2013232. https:\/\/doi.org\/10.5090\/kjtcs.2020.53.4.226","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"3720_CR35","doi-asserted-by":"publisher","first-page":"302","DOI":"10.21037\/jtd.2018.11.101","volume":"11","author":"R Zhang","year":"2019","unstructured":"Zhang R, Zhang L (2019) Management of delayed gastric conduit emptying after esophagectomy. J Thorac Dis 11:302\u2013307. https:\/\/doi.org\/10.21037\/jtd.2018.11.101","journal-title":"J Thorac Dis"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03720-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03720-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03720-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T07:29:25Z","timestamp":1650353365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03720-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3720"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03720-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"20 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patrick Sven Plum is a fellow of the Else Kr\u00f6ner Forschungskolleg Cologne \u201cClonal Evolution in Cancer\u201d (2016-Kolleg-19). All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was performed following the guidelines of the Institutional Ethics Committee of the University Hospital of Cologne and following the relevant version of the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Since only routinely collected patient data during the clinical course and our outpatient clinic has been used, no further patient consent was necessary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publication"}}]}}